# Capsaicin Improves Lipid Metabolism Disorders Caused by LPS-Induced Immune Stress in Weaned Piglets

**Authors:** Jianlei Zhao, Wenyi Liu, Xin Zhang, Zechen Xie, Shuhan Liu, Wenjun Zhou, Lili Zhang

PMC · DOI: 10.3390/vetsci13020155 · Veterinary Sciences · 2026-02-05

## TL;DR

Capsaicin helps improve lipid metabolism and reduce inflammation in young pigs under immune stress, potentially benefiting their health and growth.

## Contribution

This study demonstrates that capsaicin modulates lipid metabolism and inflammation in weaned piglets via PPARα and TRPV1 pathways, offering a novel dietary intervention.

## Key findings

- Dietary capsaicin reduces serum and liver lipid accumulation in LPS-induced piglets.
- Capsaicin activates PPARα and TRPV1 pathways to enhance fatty acid oxidation and bile acid metabolism.
- It disrupts the lipid metabolism–inflammation cycle by reducing pro-inflammatory lipid mediators.

## Abstract

Because the immune system and metabolic function of weaned piglets are not yet mature, they are vulnerable to immune stress caused by environmental and pathogenic stimulation, which often leads to lipid metabolism disorders, increased inflammation, and growth retardation. In this study, the immune stress model of weaned piglets was established by LPS induction, and the regulatory effect of capsaicin on lipid metabolism and its molecular mechanism was studied. The results showed that dietary supplementation of 800 mg/kg capsaicin significantly alleviated LPS-induced abnormal elevation of serum and liver triglycerides, non-esterified fatty acids, and low-density lipoprotein cholesterol, and improved bile acid metabolism. In terms of mechanism, capsaicin up-regulates the expression of genes and proteins in the PPARα pathway, consistent with enhanced fatty acid oxidation, down-regulates key genes of fatty acid synthesis, such as FASN and DGAT1, and cholesterol absorption-related genes such as NPC1L, and up-regulates LXRα-ABCG5 and FXR-CYP7A1-MRP4 pathways to enhance cholesterol efflux and bile acid synthesis. In addition, capsaicin also reduces the accumulation of pro-inflammatory lipid mediators such as leukotriene D4 and arachidonic acid, breaking the vicious cycle of ‘lipid metabolism–inflammation’, thereby effectively improving lipid homeostasis and overall health of weaned piglets under immune stress.

The purpose of this study was to investigate the effect of capsaicin (CAP) on lipid metabolism in weaned piglets and its related mechanisms. Twenty-four weaned piglets with an initial body weight of 9.00 ± 0.30 kg were randomly divided into three groups, with eight replicates in each group. The control (CON) and lipopolysaccharide (LPS) groups were fed a basal diet, while the LPS and capsaicin group (LCA) received the basal diet supplemented with 4 mg/kg pure capsaicin (delivered via 800 mg/kg additive) for 35 days. About 4 h before sampling, piglets in the LPS and LCA groups were intraperitoneally injected with LPS at a dose of 100 μg/kg body weight, while those in the CON group were intraperitoneally injected with the same dose of normal saline. In this study, we found that the addition of 800 mg/kg CAP to the diet of piglets significantly reduced the accumulation of serum triglyceride (TG), non-esterified fatty acids (NEFA), and liver fat, and that CAP up-regulates expression of genes and proteins in the PPARα pathway, consistent with enhanced fatty acid oxidation. The intervention with 4 mg/kg CAP was also found to down-regulate cholesterol synthesis precursors (such as mevalonate, MVA), reduce pro-inflammatory phospholipids (such as phosphatidic acid–phosphatidylcholine, PA–PC), and modulate bile acid metabolism, thereby beneficially regulating blood lipid profiles (TC, TG, LDL-C) and disrupting the “lipid metabolism–inflammation” interaction cycle. Furthermore, CAP promoted fatty acid β-oxidation and bile acid metabolism by activating the TRPV1 channel, which alleviated hepatic lipid accumulation. These findings indicated that CAP has potential application value in improving lipid metabolism, intestinal health, and immune function in weaned piglets. However, its long-term safety and dose-dependent effects require further investigation.

## Linked entities

- **Genes:** PPARA (peroxisome proliferator activated receptor alpha) [NCBI Gene 5465], FASN (fatty acid synthase) [NCBI Gene 2194], DGAT1 (diacylglycerol O-acyltransferase 1) [NCBI Gene 8694], npc1.L (NPC intracellular cholesterol transporter 1 L homeolog) [NCBI Gene 108719222], NR1H3 (nuclear receptor subfamily 1 group H member 3) [NCBI Gene 10062], ABCG5 (ATP binding cassette subfamily G member 5) [NCBI Gene 64240], NR1H4 (nuclear receptor subfamily 1 group H member 4) [NCBI Gene 9971], CYP7A1 (cytochrome P450 family 7 subfamily A member 1) [NCBI Gene 1581], ABCC4 (ATP binding cassette subfamily C member 4 (PEL blood group)) [NCBI Gene 10257]
- **Chemicals:** capsaicin (PubChem CID 1548943), leukotriene D4 (PubChem CID 5280878), arachidonic acid (PubChem CID 444899), mevalonate (PubChem CID 4478250), PA–PC (PubChem CID 5283486)

## Full-text entities

- **Genes:** Lpl (lipoprotein lipase) [NCBI Gene 16956], Ffar3 (free fatty acid receptor 3) [NCBI Gene 233080] {aka Gm478, Gpr41}, Slc27a1 (solute carrier family 27 (fatty acid transporter), member 1) [NCBI Gene 26457] {aka FATP1, Fatp, Vlc27a1}, Pla2g1b (phospholipase A2, group IB, pancreas) [NCBI Gene 18778] {aka Pla2a, sPLA2IB}, Cpt1a (carnitine palmitoyltransferase 1a, liver) [NCBI Gene 12894] {aka C730027G07, CPTI, Cpt1}, Ppara (peroxisome proliferator activated receptor alpha) [NCBI Gene 19013] {aka 4933429D07Rik, Nr1c1, PPAR-alpha, PPARalpha, Ppar}, ACACA (acetyl-CoA carboxylase alpha) [NCBI Gene 31] {aka ACAC, ACACAD, ACACalpha, ACC, ACC1, ACCA}, Ldlr (low density lipoprotein receptor) [NCBI Gene 16835] {aka Hlb301}, Fabp2 (fatty acid binding protein 2, intestinal) [NCBI Gene 14079] {aka Fabpi, I-FABP}, FASN (fatty acid synthase) [NCBI Gene 2194] {aka FAS, OA-519, SDR27X1}, Slc27a2 (solute carrier family 27 (fatty acid transporter), member 2) [NCBI Gene 26458] {aka ACSVL1, FATP2, VLCS, Vlac, Vlacs}, Tnf (tumor necrosis factor) [NCBI Gene 21926] {aka DIF, TNF-a, TNF-alpha, TNFSF2, TNFalpha, Tnfa}, PPARA (peroxisome proliferator activated receptor alpha) [NCBI Gene 5465] {aka NR1C1, PPAR, PPAR-alpha, PPARalpha, hPPAR}, Nr1h3 (nuclear receptor subfamily 1, group H, member 3) [NCBI Gene 22259] {aka LXR, RLD1, Unr1}, FAS (Fas cell surface death receptor) [NCBI Gene 355] {aka ALPS1A, APO-1, APT1, CD95, FAS1, FASTM}, Ppargc1a (peroxisome proliferative activated receptor, gamma, coactivator 1 alpha) [NCBI Gene 19017] {aka A830037N07Rik, Gm11133, PGC-1, PPARGC-1-alpha, Pgc-1alpha, Pgc1}, DGAT1 (diacylglycerol O-acyltransferase 1) [NCBI Gene 8694] {aka ARAT, ARGP1, DGAT, DIAR7}, NR1H3 (nuclear receptor subfamily 1 group H member 3) [NCBI Gene 10062] {aka LXR-a, LXRA, RLD-1}, Slc27a5 (solute carrier family 27 (fatty acid transporter), member 5) [NCBI Gene 26459] {aka FACVL3, FATP5, VLCS-H2, VLCSH2, Vlacsr}, Il6 (interleukin 6) [NCBI Gene 16193] {aka Il-6}, Fabp4 (fatty acid binding protein 4, adipocyte) [NCBI Gene 11770] {aka 422/aP2, AFABP, ALBP, ALBP/Ap2, Ap2, Lbpl}, Nr1h4 (nuclear receptor subfamily 1, group H, member 4) [NCBI Gene 20186] {aka Fxr, HRR1, RIP14, Rxrip14}, Il1b (interleukin 1 beta) [NCBI Gene 16176] {aka IL-1beta, Il-1b}, DGAT2 (diacylglycerol O-acyltransferase 2) [NCBI Gene 84649] {aka ARAT, GS1999FULL, HMFN1045}, FABP4 (fatty acid binding protein 4) [NCBI Gene 2167] {aka A-FABP, AFABP, ALBP, HEL-S-104, aP2}, Slc27a4 (solute carrier family 27 (fatty acid transporter), member 4) [NCBI Gene 26569] {aka ACSVL4, FATP4}, Tlr4 (toll-like receptor 4) [NCBI Gene 21898] {aka Lps, Ly87, Ran/M1, Rasl2-8}, Trpv1 (transient receptor potential cation channel, subfamily V, member 1) [NCBI Gene 193034] {aka OTRPC1, TRPV1alpha, TRPV1beta, VR-1, Vr1}, TRPV1 (transient receptor potential cation channel subfamily V member 1) [NCBI Gene 7442] {aka VR1}, Blnk (B cell linker) [NCBI Gene 17060] {aka BASH, Bca, Ly-57, Ly57, Lyw-57, SLP-65}
- **Diseases:** liver metabolic dysfunction (MESH:D017093), hepatic lipid (MESH:D011017), atherosclerosis (MESH:D050197), lipid metabolism disorder (MESH:D052439), cardiovascular diseases (MESH:D002318), insulin resistance (MESH:D007333), hepatobiliary diseases (MESH:D004066), cytotoxic (MESH:D064420), obesity (MESH:D009765), diarrhoea (MESH:D003967), related diseases (MESH:D000077733), metabolic (MESH:D008659), injury to (MESH:D014947), inflammation (MESH:D007249), growth retardation (MESH:D006130), mitochondrial dysfunction (MESH:D028361), dyslipidemia (MESH:D050171), vascular diseases (MESH:D014652), cancer (MESH:D009369)
- **Chemicals:** citrate (MESH:D019343), CAP (MESH:D002211), SYBR Green (MESH:C098022), steroids (MESH:D013256), taurine (MESH:D013654), ATP (MESH:D000255), pantothenic acid (MESH:D010205), iodine (MESH:D007455), cobalamin (MESH:D014805), sterol (MESH:D013261), Leukotriene D4 (MESH:D017998), LPS (MESH:D008070), Lipid (MESH:D008055), PVDF (MESH:C024865), 1-stearoyl-2-docosahexaenoyl-sn-glycero-3-phosphocholine (MESH:C409542), organoheterocyclic compounds (MESH:D006571), lysine (MESH:D008239), Tween 20 (MESH:D011136), oleic acid (MESH:D019301), BAs (MESH:D001464), threonine (MESH:D013912), folic acid (MESH:D005492), glucose (MESH:D005947), manganese (MESH:D008345), palmitoleic acid (MESH:C008757), palmitate (MESH:D010168), BA (MESH:D001647), TAG (-), lysophospholipids (MESH:D008246), glycerol (MESH:D005990), palmitoyl carnitine (MESH:D010172), thiamin (MESH:D013831), vitamin D3 (MESH:D002762), nicotinic acid (MESH:D009525), Monounsaturated fatty acids (MESH:D005229), selenium (MESH:D012643), carbohydrates (MESH:D002241), FA (MESH:D005227), acetoacetate (MESH:C016635), acylcarnitine (MESH:C116917), riboflavin (MESH:D012256), phospholipid (MESH:D010743), H2O. (MESH:D014867), eicosapentaenoic acid (MESH:D015118), myristoleic acid (MESH:C054211), vitamin A (MESH:D014801), malonyl-CoA (MESH:D008316), NEFA (MESH:D005230), nucleotides (MESH:D009711), stearic acid (MESH:C031183), AA (MESH:D016718), acetyl-CoA (MESH:D000105), iron (MESH:D007501), copper (MESH:D003300), LysoPC (MESH:C006065), oxysterol (MESH:D000072376), alkaloid (MESH:D000470), SDS (MESH:D012967), Biogenic amine (MESH:D001679), glycochenodeoxycholic acid (MESH:D005999)
- **Species:** Cavia porcellus (domestic guinea pig, species) [taxon 10141], Rattus norvegicus (brown rat, species) [taxon 10116], Homo sapiens (human, species) [taxon 9606], Sus scrofa (pig, species) [taxon 9823], Porcine reproductive and respiratory syndrome virus (no rank) [taxon 28344], Escherichia coli (E. coli, species) [taxon 562], Mus musculus (house mouse, species) [taxon 10090]

## Full text

_Full body text omitted from this summary view._ Fetch the complete paper as Markdown: https://tomesphere.com/paper/PMC12945166/full.md

## Figures

5 figures with captions in the complete paper: https://tomesphere.com/paper/PMC12945166/full.md

## References

71 references — full list in the complete paper: https://tomesphere.com/paper/PMC12945166/full.md

---
Source: https://tomesphere.com/paper/PMC12945166